High intravitreal TGF-[beta]1 and MMP-9 levels in eyes with retinal vein occlusion

• Published in: Eye (London) 2014-09, Vol.28 (9), p.1095
• Main Authors: Tuuminen, R, Loukovaara, S
• Format: Article
• Language: English
• ISSN: 0950-222X; 1476-5454
• DOI: 10.1038/eye.2014.137

Vascular endothelial growth factor is a leading target to reduce macular oedema and improve visual acuity in patients with retinal vein occlusion (RVO), whereas the role of vascular destabilizing and fibroproliferative transforming growth factor (TGF)-[beta]1 and matrix metalloproteinases (MMP)-2 and -9 in pathological manifestations of RVO is anticipated but less studied. Undiluted vitreous samples were collected from three central RVO and one branch RVO eyes, all with neovascularization and fibrosis-related sight-threatening complications of RVO. Undiluted vitreous samples of 40 eyes operated due to non-ischemic condition either macular hole or pucker were used as controls. Growth factor and protease concentrations were measured by ELISA and gelatin zymography. Vitreous concentrations of TGF-[beta]1 (92.0 ± 17.4 pg/ml vs 18.3 ± 27.0 pg/ml, mean ± SD; P=0.002) and MMP-9 (847.9 ± 1196.4AU/ml vs 87.7 ± 174.0 AU/ml; P=0.010) were higher in the eyes with ischemic RVO than in the controls. High intravitreal levels of TGF-[beta]1 and MMP-9 are found in RVO eyes having neovascular and fibrosis manifestation. Further studies are warranted to elucidate whether targeting TGF-[beta]1 and MMP-9 could be beneficial in patients with ischemic RVO.